Short answer
Vir Biotechnology, Inc. (VIR) filed an 8-K current report with the SEC on July 24, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). CFO Jason O’Byrne departing August 3, 2026 to pursue another opportunity.
Vir Biotechnology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CFO Jason O’Byrne departing August 3, 2026 to pursue another opportunity
- Resignation unrelated to disagreements over Vir Bio’s operations, policies, or practices
- Chief Accounting Officer Brent Sabatini appointed interim principal financial officer effective August 3, 2026
- Vir Bio has begun searching for a permanent CFO
- Interim appointment carries no additional compensation or conflicts disclosed
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vir Biotechnology, Inc. 8-K filings
Get the next VIR 8-K as it lands
Follow VIR for push alerts, or ask the research agent what this filing means.